Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers

被引:65
作者
Min, DI
Lee, M
Ru, YM
Flanigan, M
机构
[1] Univ Iowa, Coll Pharm, Div Clin & Adm Pham, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA
关键词
D O I
10.1067/mcp.2000.111255
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacokinetic studies of intravenous and oral cyclosporine (cyclosporin) were performed in 22 healthy African American (n = 11) and white (n = 11) volunteers. Blood cyclosporine concentrations were measured by high performance liquid chromatography, Concentration versus time data were analyzed by noncompartmental models, and statistical analyses were performed by ANOVA, The clearance of intravenous and oral cyclosporine was 4.3 +/- 0.9 mL/min/kg and 13.5 +/- 4.5 mL/min/kg, respectively, in African Americans and 3.7 +/- 0.5 mL/min/kg and 9.6 mL/min/kg, respectively in the white volunteers (P =.0001). There was a significant race and gender interaction (P =.038), Bioavailability was lower in African Americans (32.8 +/- 6.6%) compared with white volunteers (39.3 +/- 7.1%; P =.049), with a significant race and gender interaction (P =.048). The dose-adjusted area under the curve (AUC) of intravenous and oral cyclosporine was 54.3 +/- 10.6 ng.hr/mL per milligram and 18.1 +/- 4.1 ng.hr/mL per milligram, respectively, in African Americans and 61.9 +/- 6.8 ng.hr/mL per milligram and 24.2 +/- 4.6 ng.hr/mL per milligram, respectively, in white volunteers (P =.023). These findings suggest that disposition of cyclosporine is dependent both on race and on gender.
引用
收藏
页码:478 / 486
页数:9
相关论文
共 21 条
  • [1] ETHNIC-DIFFERENCES IN THE PHARMACOKINETICS OF ORAL NIFEDIPINE
    AHSAN, CH
    RENWICK, AG
    MACKLIN, B
    CHALLENOR, VF
    WALLER, DG
    GEORGE, CF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (04) : 399 - 403
  • [2] Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4
    Ball, SE
    Scatina, JA
    Kao, J
    Ferron, GM
    Fruncillo, R
    Mayer, P
    Weinryb, I
    Guida, M
    Hopkins, PJ
    Warner, N
    Hall, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (03) : 288 - 294
  • [3] First MR, 1996, CLIN TRANSPLANT, V10, P55
  • [4] KAHAN BD, 1989, NEW ENGL J MED, V321, P1725
  • [5] KOVARIK JM, 1994, TRANSPLANTATION, V58, P658
  • [6] CYCLOSPORINE METABOLISM IN HUMAN-LIVER - IDENTIFICATION OF A CYTOCHROME-P-450III GENE FAMILY AS THE MAJOR CYCLOSPORINE-METABOLIZING ENZYME EXPLAINS INTERACTIONS OF CYCLOSPORINE WITH OTHER DRUGS
    KRONBACH, T
    FISCHER, V
    MEYER, UA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (06) : 630 - 635
  • [7] Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: Does the formulation difference matter?
    Ku, YM
    Min, DI
    Flanigan, M
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (10) : 959 - 965
  • [8] INFLUENCE OF CYCLOSPORINE PHARMACOKINETICS, TROUGH CONCENTRATIONS, AND AUC MONITORING ON OUTCOME AFTER KIDNEY-TRANSPLANTATION
    LINDHOLM, A
    KAHAN, BD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (02) : 205 - 218
  • [9] DEMOGRAPHIC-FACTORS INFLUENCING CYCLOSPORINE PHARMACOKINETIC PARAMETERS IN PATIENTS WITH UREMIA - RACIAL-DIFFERENCES IN BIOAVAILABILITY
    LINDHOLM, A
    WELSH, M
    ALTON, C
    KAHAN, BD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (04) : 359 - 371
  • [10] FACTORS INFLUENCING THE PHARMACOKINETICS OF CYCLOSPORINE IN MAN
    LINDHOLM, A
    [J]. THERAPEUTIC DRUG MONITORING, 1991, 13 (06) : 465 - 477